Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3NETWORK 3INDUSTRY 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 1FGFR1 Gene Amplification 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 214Cisplatin 180Cyclophosphamide 169Doxorubicin 138Vincristine 127Paclitaxel 125Filgrastim 121Etoposide 104Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NETWORK × AZD4547 × Clear all
NCT01824901 2023-06-29

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Completed
2 enrolled 4 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
43 enrolled 15 charts

FGFR1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡